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Key messages
What is already known about this subject?
 ► Coronary collateralisation, occurring particularly 
in the presence of coronary artery disease (CAD), 
is considered protective in the case of myocardial 
infarction.
 ► Ischaemic preconditioning increases arteriogenesis 
in rats and rabbits.
What does this study add?
 ► In this study on ischaemia-induced and reperfu-
sion-induced injury, we found that the most widely 
used cardioprotective drugs in CAD unfavourably 
impacted the cardiac outcomes in rats after isch-
aemic preconditioning.
How might this impact on clinical practice?
 ► Care should be taken in the selection of cardiopro-
tective drugs.
 ► Further research in experimental and clinical set-
tings is necessary to elucidate the impact of con-
comitant medication on clinical outcomes.
AbstrAct
Objective We investigated the impact of cardioprotective 
drugs on ST-elevation, arrhythmias and infarct size in a rat 
model of repetitive coronary artery occlusion.
Methods Seventy Sprague-Dawley rats were randomised 
to two control and five treatment groups. Placebo was 
either implantation of a pneumatic occluder onto the left 
anterior descending coronary artery (LAD) without starting 
repetitive occlusion (SHAM) or subsequent RO of the LAD 
over 10 days without medication (ROP). Treatment groups 
underwent RO and additionally received nitroglycerin 
(NTG), metoprolol, verapamil (VER), ranolazine (RAN) or 
candesartan (CAN). Two weeks after the intervention, rats 
underwent a single, sustained LAD occlusion followed by 
reperfusion. To evaluate differences in cardiac resistance 
against myocardial ischaemia and reperfusion injury, 
cardiac surrogate parameters including maximal ST-
elevation, arrhythmias and infarct size were assessed.
Results Compared with sham, RO alone and RO plus 
nitroglycerin were associated with significantly lower 
maximal ST-elevation and percentage of infarcted 
myocardium (SHAM 0.12 mV, ROP 0.06 mV (p=0.004), 
NTG 0.05 mV (p=0.005); SHAM 16.2%, ROP 6.6% 
(p=0.008), NTG 5.9% (p=0.006). Compared with RO alone, 
RO plus RAN was accompanied by increased ST-elevation 
(0.13 mV, p=0.018) and RO plusVER or CAN by more 
infarcted myocardium (14.2%, p=0.004% and 15.5%, 
p=0.003, respectively). Rats treated with VER, RAN or CAN 
tended to severe arrhythmias more frequently than those 
of the control groups.
Conclusions RO led to an increased myocardial 
resistance against ischaemia and reperfusion injury. 
Concomitant administration of nitroglycerin did not affect 
the efficacy of RO. Cardiovascular channel or receptor 
blockers reduced the efficacy of RO.
IntROduCtIOn
The rate of coronary artery disease (CAD) 
has declined during the first decade of the 
21st century.1 However, myocardial infarction 
remains a possibly fatal consequence. Coro-
nary collateralisation, occurring particularly 
in the presence of CAD with repeat episodes 
of angina, is considered protective in the case 
of myocardial infarction. Sustained perfusion 
of ischaemic tissue by coronary anastomoses 
reduces ST-elevation, fatal arrhythmias, 
infarct size and mortality.2–5 Therefore, ther-
apeutic promotion as well as prevention of 
impairment of collateral growth and signal 
pathways of myocardial preconditioning may 
improve survival from myocardial infarction.
Collateral growth, referred to as arte-
riogenesis, is a physiological response to 
enhanced blood flow to compensate for 
tissue hypoxia and ischaemia. It includes 
proliferation and transformation of pre-ex-
isting bridging arterial vessels into functional 
arterial anastomoses with enlarged calibres. 
Arteriogenesis is benefited by a low heart rate 
and the absence of hypertension.6 Addition-
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Ischaemic preconditioning induces complex signal 
cascades, which stimulate arteriogenesis and reduce 
myocardial ischaemia and reperfusion-induced injury. 
Stimuli such as calcium ions, reactive nitrogen species, 
autacoids, neurohormones and growth factors acti-
vate kinase pathways including endothelial nitric oxide 
synthase finally converge in mitochondria, which are 
necessary to provide ATP for the maintenance of cellular 
integrity and the prevention of cardiomyocyte death.8 9
Patients with CAD most frequently are treated with 
antianginal or antihypertensive drugs. However, little 
is known whether and how these medications interact 
with cardioprotective signal pathways and myocardial 
arteriogenesis. A previous study on a rat model of repet-
itive myocardial ischaemia showed an increased collater-
al-dependent flow after completion of a 10-day repetitive 
coronary artery occlusion (RO) protocol compared with 
sham treatment.10 Based on this finding, the objective of 
this study was to assess whether different cardiovascular 
medications in addition to RO affect cardiac resistance 




In a model of repetitive myocardial ischaemia, male 
Sprague-Dawley rats, aged 10–12 weeks, underwent 
repetitive occlusion (RO) of the left anterior descending 
coronary artery (LAD) to stimulate myocardial arterio-
genesis. For this purpose, a pneumatic mini-occluder was 
implanted under general anaesthesia and postprocedural 
analgesia as described before.10 RO started 3 days after 
implantation of the occluder onto the heart at the level of 
the mid to proximal LAD. RO-induced recurrent myocar-
dial ischaemia was induced by automated compression of 
the LAD three times a day for 10 days. One 40 s occlusion 
was performed every 20 min for 2 hours 20 min, followed 
by 5 hours 40 min of rest (figure 1A,B). From the second 
day after implantation of the occluder and, in parallel 
with RO over a period of 10 days, the animals received 
cardiovascular drugs or placebo.
Seventy rats were randomly allocated to five treatment 
and two control groups. Treatment group animals received 
nitroglycerin (NTG group: 17.37 µg nitroglycerin twice 
daily), ß1-blockers (MET group: metoprolol 190 mg/
kg/day), L-type calcium-cannel blockers (VER group: 
verapamil 22 mg/kg/day), sodium channel blockers 
(RAN group: ranolazine 62 mg/kg/day) or angiotensin 
II type 1 receptor blockers (CAN group: candesartan 2 
mg/kg/day). Drugs were dissolved in water and applied 
by oral gavage using a flexible esophageal probe. Control 
group animals received a placebo treatment of 0.5 mL 
water once daily for 10 days in parallel with RO (ROP 
control group) or without RO (SHAM control group).
One day after completion of RO and 2 days after termi-
nation of treatment, a myocardial infarction was induced 
in all animals artificially by sustainedLAD occlusion for 
90 min. After subsequent reperfusion for 20 min, rats 
were anaesthetised and sacrificed by CO2. Subsequently, 
their hearts were eviscerated for structural evaluation 
(figure 1C).
Outcome measures
Functional outcome measures were maximal ST-seg-
ment elevation and ventricular arrhythmias according 
to Lown’s grading during the final occlusion. Struc-
tural outcome measure was the volume fraction of the 
infarcted myocardium. Cardiac structural and functional 
outcomes were considered representative for the extent 
of collateralisation.
electrocardiography
ST-segment elevation is considered a quantitative indi-
cator of collateral function.5 6 It is strongly related to 
infarct size and mortality. Therefore, maximum ST-seg-
ment elevation within the first 30 min of final occlusion 
was determined using LabChart data analysis software 
(ADInstruments, Oxford, UK). Any pre-existing ST-seg-
ment elevation 30 s prior to final occlusion was consid-
ered as baseline.
Arrhythmias were categorised according to Lown’s 
grading of ventricular arrhythmia: 0=no ventricular 
premature beats (VPB), I=unifocal (<30 PVB/hour), 
II=unifocal and frequent (>1/min or ≥30/hour), IIIb=sys-
tematised ventricular extrasystoles (bigeminy), IVa=2 
consecutive beats (couplets), IVb =≥3 consecutive beats 
(salvos), V=R on T. For analysis, categories were allocated 
to a VPB score, scaled from 1 to 7.
Infarct volume
Constant location and time of occlusion provided, 
infarct volume indicates directly the collateral supply.6 11 
Volume of the infarcted myocardium was evaluated by 
2,3,5-triphenyltetrazolium chloride (TTC) staining as 
described below.
After final sustained LAD occlusion and subsequent 
reperfusion for 20 min, hearts were perfused with phos-
phate-buffered saline solution. Thereafter, left ventricles 
were frozen at −20°C for 10 min and cut in 2 mm sections. 
Left ventricles were then incubated in TTC solution for 
20 min at 37°C and transferred to 4% formalin for 15 
min. Infarcted myocardium is TTC negative and there-
fore becomes visible as pale pink tissue. Images were 
taken with Canon Super Shot S70 and acquired on a 
Leica MZ6 microscope.
The infarct volume was calculated from the determined 
infarct area of every section of the sliced left ventricle, 
multiplied by number and thickness of the sections. 
Infarct volume was expressed as a percentage from the 
left ventricle.
statistical analysis
Continuous variables are reported as mean±SD. Means 
are presented with their corresponding 95% CIs. Differ-
ences between means were compared by Dunett’s 
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Figure 1 Study flow chart. Repetitive occlusion protocol (ROP) (A, B) and study setup (C). CAN, candesartan group; MET, 
metoprolol group; NTG. nitroglycerin group; RAN, ranolazine group; ROP, repetitive occlusion protocol group; SHAM, control 
group without repetitive occlusion; VER, verapamil group; VPS, ventricular premature beats.
compare categorical variables. A two-sided value of p<0.05 
indicated statistical significance. Statistical analyses were 




Maximal ST-elevation during final occlusion was signif-
icantly decreased in the ROP and the NTG group 
compared with SHAM. Rats treated with RO plus metopr-
olol, verapamil, ranolazine or candesartan did not differ 
significantly from SHAM but showed an increased ST-el-
evation compared with the ROP group. However, only 
the difference between the RAN and the ROP group was 
significant (figure 2A, table 1).
None of the treatment groups differed significantly 
from the SHAM or the ROP group with regard to 





















4 Gatzke N, et al. Open Heart 2018;5:e000889. doi:10.1136/openhrt-2018-000889
Figure 2 Effect of sustained left anterior descending 
coronary artery (LAD) occlusion and reperfusion on ECG 
findings and volume fraction of the infarcted myocardium. 
Maximal ST-segment elevation (A) and arrhythmias (B) 
were assessed during 90 min of final occlusion. Differences 
between means were compared by Dunett’s multiple 
comparison. Means are pictured as diamonds with their 
corresponding 95% CIs (A, C). The Kruskall-Wallis test was 
used to determine whether proportions of arrhythmia grading 
differed significantly between each group and sham or ROP. 
(B). Lown’s grading of arrhythmia: 0=no ventricular premature 
beats (VPB), I=unifocal (<30 PVB/hour), II=unifocal and 
frequent (>1/min or ≥30/hour), IIIb=systematised ventricular 
extrasystoles (bigeminy), IVa=2 consecutive beats (couplets), 
IVb =≥3 consecutive beats (salvos), V=R on T. A value of 
p<0.05 indicated statistical significance versus ROP* or vs 
SHAM**. Number of analysed animals is given in table 1. 
CAN,candesartan group; MET, metoprololgroup; NTG, 
nitroglycerin group; RAN, ranolazinegroup; ROP, repetitive 
occlusionprotocol group.
ventricular premature beat (VPB) score was lowest in the 
ROP group. Rats treated with verapamil, ranolazine or 
candesartan showed a tendency to higher VPB scores 
(figure 2B, table 1).
structural outcome
Percentage of infarcted myocardium by volume was signif-
icantly lower in the ROP and the NTG group compared 
with the SHAM. As with ST-elevation, none of the treat-
ments increased infarct size compared with SHAM. The 
SHAM, VER, RAN and CAN groups showed larger infarct 
sizes than the ROP group with significant differences for 
SHAM, VER and CAN (figure 2C, table 2).
dIsCussIOn
In this study on myocardial resistance in a rat model of 
repetitive coronary artery occlusion, we found that the 
most frequently used cardioprotective drugs in CAD 
unfavourably impacted the cardiac outcomes.
As expected, the ROP control showed improved func-
tional and structural cardiac outcomes after sustained 
LAD occlusion and reperfusion compared with the 
sham control. Presumably, this was due to RO-induced 
enhanced collateralisation and thus reduced ischaemia. 
Additionally, RO might have served as preconditioning of 
reperfusion. After all, reperfusion injury accounts for up 
to 50% of infarct size in animal models due to oxidative 
stress, cell swelling, intracellular calcium overload, lactid 
acid washout and inflammation, all of which mediate 
cardiomyocyte death.11–15 However, whether repeat 
episodes of angina in patients with CAD similarly precon-
dition their myocardium remains speculative.
Results after concomitant treatment with metoprolol, 
verapamil, ranolazine or candesartan did not differ 
significantly from the sham treatment, which suggests 
that those medications negatively affected cardioprotec-
tive signal cascades. Moreover, results from verapamil, 
ranolazine and candesartan tended to be worse than 
those from metoprolol. In contrast, RO plus nitroglyc-
erin medication improved the cardiac outcome similar 
to RO alone. From this, it can be derived that nitroglyc-
erin did not negatively affect signal transduction and 
arteriogenesis.
Cardioprotection including collateral growth can 
be achieved by different therapeutic or experimental 
approaches such as external counterpulsation, endur-
ance exercise training,6 16 administration of vascular 
growth factors,17 granulocyte colony-stimulating factor18 
and blocking of natural inhibitors such as interferon-ß 
receptors.19 Therefore, one might suspect that even 
common cardiovascular medications for patients with 
CAD may affect the balance of promotion and inhibition 
of cardiac resistance.
nitroglycerin
Nitroglycerin is widely administered for rapid coronary 
vasodilation. The active metabolite of nitroglycerin, nitric 
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Table 1 Functional outcomes after cardiovascular medication in a rat model of repetitive myocardial ischaemia
SHAM ROP NTG MET VER RAN CAN
Max. ST-elevation (mV)* n=7 n=7 n=6 n=6 n=7 n=8 n=7
Mean±SD 0.124±0.039 0.055±0.033 0.054±0.031 0.074±0.063 0.122±0.055 0.13±0.063 0.111±0.062
95% CI 0.088 to 0.16 0.02 to 0.086 0.021 to 0.087 0.008 to 0.14 0.071 to 0.173 0.077 to 0.183 0.054 to 0.168
P value (vs ROP) 0.004 – 0.956 0.505 0.203 0.018 0.064
P value (vs SHAM) – 0.004 0.005 0.114 0.939 0.832 0.649
VPB† n=7 n=7 n=6 n=6 n=6 n=8 n=7
VPB score 4.43 2.86 3.00 3.00 5.83 4.50 5.00
P value (vs ROP) 0.848 – 0.999 0.999 0.055 0.455 0.265
P value (vs SHAM) – 0.848 0.976 0.999 0.660 0.986 0.955
*Maximal ST-elevation during 90 min of LAD occlusion.
†Ventricular arrhythmia categorised according to Lown’s grading of 0 to V and the associated VPS score of 1 to 7.
CAN, candesartan group; MET, metoprololgroup; NTG, nitroglycerin group; RAN, ranolazinegroup; ROP, repetitive occlusionprotocol group; 
VPS, ventricular premature beats.
















Mean±SD 16.2±6.2 6.6±3.3 5.9±3.5 9.9±4.4 14.2±4.1 14.6±10.1 15.5±4.4
95% CI 10.4 to 21.9 3.3 to 10.0 2.3 to 9.6 5.2 to 14.5 10.4 to 18.0 5.3 to 24.0 10.8 to 20.1
P value (vs ROP) 0.008 – 0.750 0.175 0.004 0.104 0.003
P value (vs SHAM) – 0.008 0.006 0.065 0.502 0.738 0.818
*Volume fraction of infarcted myocardium of the left ventricle after sustainedLAD occlusion and reperfusion.
CAN, candesartan group; LAD, left anterior coronary artery; MET, metoprolol group; NTG, nitroglycerin group; RAN, ranolazine group; ROP, 
repetitive occlusion protocol group; SHAM, control group without ROP; VER, verapamil group.
as a consequence of increased pulsatile, tangential fluid 
shear stress (FSS) within collateral vessels in the event of 
an upstream flow-limiting stenosis. Additionally, NO itself 
increases the pressure gradient and therefore, the FSS. 
Thus, NO leads to a flow-mediated vasodilation and addi-
tionally facilitates the cascade of vascular remodelling to 
activate structural modification.7 In this rat model, NO 
from nitroglycerin medication and naturally released 
NO from repetitive occlusion might have comple-
mented, but not enhanced one another in their effect 
on arteriogenesis. Possibly, endogenous NO was already 
maximally released during RO, analogue to results 
from administration of nitroglycerin during exercise.20 
However, previous studies found an impaired endothelial 
nitric oxide synthase (NOS) pathway in elderly patients 
with CAD, which goes along with decreased collateral 
growth.21 Therefore, nitroglycerin medication in the case 
of impaired nitric oxide metabolism might be an issue of 
further research.
ß-Blockers
Beta-blockers are competitive antagonists for endog-
enous catecholamines and therefore lower the heart 
rate, which is actually considered to promote collater-
alisation.5 6 The underlying mechanism is a prolonged 
diastole with an increased coronary flow, followed by 
the upregulation of NOS19 and enhanced FSS as the 
main trigger of arteriogenesis.22 However, previous 
studies23–25 reported on an impaired collateral flow with 
ß1 and ß2-blockers, probably due their vasoconstrictive 
effect on collaterals and the reduced oxygen demand. 
Additionally, ß1 and ß2-blockers were found to decrease 
NOS and vascular endothelial growth factors (VEGF) in 
embryoid bodies.26 These findings are in the line with 
the results of this study, which showed that metoprolol 
slightly impaired the effect of RO. Negative inotropic 
effects such as reduced extravascular compression 
forces, increased diastolic filling interval and improved 
oxygen supply by ß-blockers27 might have prevented 
outcome from getting worse. In contrast, studies on the 
sinus node activity inhibitor ivabradine, which induces 
bradycardia without affecting myocardial contractility, 
showed an augmented collateral function in patients 
with CAD.28 Moreover, the unselective ß-blocker and 
α1-antagonist carvedilol promotes arteriolar vasodila-
tion. It proved to be superior to metoprolol with regards 
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Verapamil
Calcium-channel blockers (CCBs) are potent vasodila-
tors. In this study, verapamil impaired the arteriogenetic 
effect of RO. By analogy, Kohro et al found a delete-
rious effect of CCBs regarding cardiovascular events in 
patients presenting with myocardial infarction during a 
3-year follow-up.30 One possible explanation might be 
a coronary steal from microvascular vasodilation.31 The 
blood flow is drained away from the collateral-dependent 
ischaemic myocardium accompanied by a decreased 
pressure gradient and FSS within the collateral vessels, 
which should have triggered arteriogenesis.
Ranolazine
Ranolazine reduces the intracellular sodium dependent 
calcium overload during myocardial ischaemia and 
thereby prevents electrical instability, reduced contrac-
tility and increased diastolic tension.32 In patients with 
CAD, angina frequency and total exercise duration were 
shown to improve with ranolazine.33 However, ranola-
zine did not reduce adverse cardiovascular events or 
the angina frequency after incomplete coronary revas-
cularisation.34 35 In this study, ranolazine plus RO came 
off worse than RO alone. The underlying mechanism 
is not yet fully understood. However, calcium entry into 
vascular endothelial cells is known to activate NOS and 
there is a functional interaction between endothelial 
sodium-calcium exchange (NCX) and NOS.36 Calcium 
influx through reverse mode NCX is required for VEGF 
signaling.37 From this it can be derived that ranolazine 
might have impeded the upregulation of NOS and there-
fore impaired collateralisation.
Candesartan
Angiotensin II type1 receptor blockers (ARB) are 
suspected to improve coronary endothelial function 
by improving the NO bioavailability.38 However, the 
renin-angiotensin system (RAS) with its active peptide 
Angiotensin II is a major determinant in cardiac remod-
elling and thus, RAS blockade by candesartan attenu-
ates remodelling. Candesartan was found to inhibit the 
expression of vascular endothelial growth factor and the 
proliferation of endothelial progenitor cells.39 40 Overall, 
mode and extent of interaction between ARBs and arte-
riogenesis, particularly regarding myocardial infarction 
and cancer, is still controversial. However, the findings 
from this study of a trend towards worse functional and 
significantly worse structural outcome with candesartan 
under the condition of myocardial ischaemia compared 
with RO alone confirm the existing knowledge.
limitations
The study design did not include the assessment of the 
treatment effect of cardiovascular drugs in the absence of 
RO and, therefore, does not permit any final conclusion 
concerning the efficacy of the studied drugs regarding 
cardiac resistance against ischaemia and reperfusion. 
Moreover, arteriogenesis was only indirectly concluded 
from functional and structural cardiac outcomes after 
coronary occlusion, but not from comparative imaging 
of the coronary microvasculature or blood flow measure-
ment. However, the rationale of this study was in accord-
ance with previous findings from a rat model on repetitive 
occlusion, which included microvascular imaging and 
blood flow measurement. Infarct size has been reported 
as a percentage of the left ventricle, not of the anatomic 
area of risk. Therefore, variation in vascular anatomy 
had not been taken into account. In humans, CAD and 
myocardial infarction is an inflammatory condition, and 
frequently patients suffer from coexisting diseases, which 
were both not reflected in this rat model.
COnClusIOn
A sufficiently developed and functioning coronary collat-
eralisation is an important predictor for survival after 
myocardial infarction in patients with CAD. In this rat 
model of repetitive myocardial ischaemia, cardiovascular 
medications turned out to reduce RO-induced myocar-
dial resistance against ischaemia-induced and reperfu-
sion-induced injury, represented by functional and struc-
tural cardiac outcome measures. This may have been 
mainly attributable to a reduced NOS activation by way 
of a decreased oxygen demand (metoprolol), microvas-
cular vasodilation (verapamil), alteration of endothelial 
sodium-calcium exchange (ranolazine) or RAS blockade 
(candesartan). Metoprolol tended to impair cardiac 
resistance to a less extent, probably, due to its protective, 
negative inotropic effect. Nitroglycerin did not affect 
cardiac resistance beyond the level already achieved by 
repetitive occlusion. However, the experimental setting 
of this pilot study does not allow for final conclusions 
regarding the treatment of patients with CAD.
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The following reference should be included in this article:
41. Gatzke N, Hillmeister P, Dülsner A, et al. Nitroglycerin application and coronary 
arteriogenesis. PloS One 2018;13:e0201597.
This reference should be cited in two places:
(1) Figure 2 legend (behind NTG, nitroglycerin group):
“Maximal ST-segment elevation (A) and arrhythmias (B) were assessed during 90 min 
of final occlusion. Differences between means were compared by Dunett’s multiple 
comparison. Means are pictured as diamonds with their corresponding 95% CIs (A, 
C). The Kruskall-Wallis test was used to determine whether proportions of arrhythmia 
grading differed significantly between each group and sham or ROP. (B). Lown’s 
grading of arrhythmia: 0=no ventricular premature beats (VPB), I=unifocal (1/min 
or ≥30/hour), IIIb=systematised ventricular extra systoles (bigeminy), IVa=2 consec-
utive beats (couplets), IVb=≥3 consecutive beats (salvos), V=R on T. A value of p<0.05 
indicated statical significance vs ROP* or vs SGAM**. Number of analysed animals is 
given in table 1. CAN, candesartan group; MET, metoprolol group; NTG, nitroglycerin 
group41; RAN, ranolazine group; ROP, repetitive occlusion protocol group.”
(2) The Discussion section (Nitroglycerin topic, after the first sentence):
“Nitroglycerin is widely administered for rapid coronary vasodilation.41”
(3) Table 1 legend (behind NTG, nitroglycerin group):
*Volume fraction of infarcted myocardium of the left ventricle after sustainedLAD 
occlusion and reperfusion.
CAN, candesartan group; LAD, left anterior coronary artery; MET, metoprolol 
group; NTG, nitroglycerin group41.
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